Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
2(40%)
Results Posted
0%(0 trials)
Terminated
1(20%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_3
2
40%

Phase Distribution

0

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
3(60.0%)
Phase 3Large-scale testing
2(40.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

2

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Active, not recruiting2
Completed2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
2
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 23 (60.0%)
Phase 32 (40.0%)

Trials by Status

active_not_recruiting240%
terminated120%
completed240%

Recent Activity

2 active trials
Showing 5 of 5
active_not_recruitingphase_3

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480
active_not_recruitingphase_3

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

NCT03478488
completedphase_2

Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

NCT05517239
completedphase_2

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC

NCT01267344
terminatedphase_2

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

NCT00127595

Clinical Trials (5)

Showing 5 of 5 trials
NCT05771480Phase 3

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

Active Not Recruiting
NCT03478488Phase 3

Programmed Death Ligand (PD-L1) Combined With Chemotherapy for Patients With BTC

Active Not Recruiting
NCT05517239Phase 2

Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

Completed
NCT01267344Phase 2

A Randomized Study of GEMOX With or Without Cetuximab in Locally Advanced and Metastatic BTC

Completed
NCT00127595Phase 2

Oxaliplatin With Gemcitabine in Patients With Carcinoma of the Urothelial Tract

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5